Company Active LTD

Company profile

Janssen-Cilag Limited

Janssen-Cilag Limited is a UK company with status active founded in 1971 based in South East England.

CRN
01027904
Founded
1971
Age
54

Overview

Legal name
JANSSEN-CILAG LIMITED
Region
South East England
Registered address
50-100 HOLMERS FARM WAY
HIGH WYCOMBE
BUCKINGHAMSHIRE
HP12 4EG
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller Controls 1
1
Company Active LTD
Janssen-Cilag Limited
CRN 01027904
2
Direct and ultimate controller
NOT APPLICABLE
CRN NOT APPLICABLE

Company events

Reference milestones and recent Companies House filing stream events.

7 events
24 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

02 Apr
2026

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzUxNDEzNjA1NmFkaXF6a2N4

Published 02 Apr 2026 15:30

10 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

29 Dec
2024

Accounts filed

Accounts

Last accounts made up date

16 Oct
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQzOTUzNjg1MWFkaXF6a2N4

Published 16 Oct 2024 10:25

19 Oct
1971

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2011
Funded years
2011
Age at first award
40 years

Projects

2011 Collaborative R&D Lead participant

Stratified Medicine Business Platform

1 Nov 2011 to 30 Nov 2013

Awarded
£59,897
Total cost £154,414

Janssen UCL Medicinal Personalization “JUMP” TSB-SM 1101 CRD MED DBM 60171/101020 Stratified medicine opens up opportunities to significantly improve treatment outcomes in patient care while at the same time providing important new avenues to reduce costs. Stratified medicine does not only promise to upend existing structures governing clinical practice, ...

2011 Collaborative R&D

Next Generation Sequencing Analysis: A Clinical Study to Implement An Innovative Cancer Care Model In the UK with Health and Economic Benefits

1 Nov 2011 to 31 Oct 2014

Awarded
£42,917
Total cost £200,137

Molecular diagnostic tests have improved quality and reduced costs of cancer care, and are becoming more widely adopted in the NHS. The proposed programme will use novel next generation sequencing (NGS) and informatics to develop consistent, accurate tests for tumour profiling in order to identify therapeutic options, including enrolment into clinical tri...

Product types

Collaborative R&D